LIVIVO - Search results -

Search results

Result 1 - 10 of total 210

Search options

Article ; Online: Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.

Emma, Callanan / Vesela, Petkova / Kay, Polly / Huseyin, Huseyin / Alison, Hassett / Mara, Sittampalam / Floriana, De Angelis / Sara, Collorone

Multiple sclerosis (Houndmills, Basingstoke, England)

2024 , Page(s) 13524585241232277

Abstract: We present a case of a 30-year-old man with relapsing-remitting multiple sclerosis who developed psoriasiform dermatitis following his second course of ocrelizumab. This resolved with topical therapies and discontinuation of treatment. Cases of ... ...

Abstract	We present a case of a 30-year-old man with relapsing-remitting multiple sclerosis who developed psoriasiform dermatitis following his second course of ocrelizumab. This resolved with topical therapies and discontinuation of treatment. Cases of psoriasiform rashes have been increasingly reported in the use of ocrelizumab and are possibly due to B-cell (CD20) depletion and T-cell overregulation. Nevertheless, skin-related adverse reactions are not yet considered in the risk management plans of anti-CD20 treatments in multiple sclerosis.
Language	English
Publishing date	2024-02-22
Publishing country	England
Document type	Journal Article
ZDB-ID	1290669-4
ISSN	1477-0970 ; 1352-4585
ISSN (online)	1477-0970
ISSN	1352-4585
DOI	10.1177/13524585241232277
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4428: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Novel Multiple Sclerosis Drugs in the Pipeline.

De Angelis, Floriana / Chataway, Jeremy

Clinical pharmacology and therapeutics

2019 Volume 105, Issue 5, Page(s) 1082–1090

MeSH term(s)	Anti-Inflammatory Agents/classification ; Anti-Inflammatory Agents/pharmacology ; Antibodies, Monoclonal/classification ; Antibodies, Monoclonal/pharmacology ; Clinical Trials as Topic ; Disease Progression ; Drug Development/methods ; Drug Discovery ; Humans ; Immunosuppressive Agents/classification ; Immunosuppressive Agents/pharmacology ; Medication Therapy Management ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/immunology ; Multiple Sclerosis, Relapsing-Remitting/diagnosis ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/immunology ; Patient Acuity ; Secondary Prevention/methods ; Therapies, Investigational
Chemical Substances	Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Immunosuppressive Agents
Language	English
Publishing date	2019-04-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	123793-7
ISSN	1532-6535 ; 0009-9236
ISSN (online)	1532-6535
ISSN	0009-9236
DOI	10.1002/cpt.1412
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 20: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Disease-modifying therapies for multiple sclerosis.

De Angelis, Floriana / John, Nevin A / Brownlee, Wallace J

BMJ (Clinical research ed.)

2018 Volume 363, Page(s) k4674

MeSH term(s)	Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cost-Benefit Analysis ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Multiple Sclerosis/drug therapy ; Practice Guidelines as Topic
Chemical Substances	Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents
Language	English
Publishing date	2018-11-27
Publishing country	England
Document type	Journal Article
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj.k4674
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.

Bianchi, Alessia / Cortese, Rosa / Prados, Ferran / Tur, Carmen / Kanber, Baris / Yiannakas, Marios C / Samson, Rebecca / De Angelis, Floriana / Magnollay, Lise / Jacob, Anu / Brownlee, Wallace / Trip, Anand / Nicholas, Richard / Hacohen, Yael / Barkhof, Frederik / Ciccarelli, Olga / Toosy, Ahmed T

Multiple sclerosis (Houndmills, Basingstoke, England)

2024 , Page(s) 13524585241240420

Abstract: Background: Optic neuritis (ON) is a common feature of inflammatory demyelinating diseases (IDDs) such as multiple sclerosis (MS), aquaporin 4-antibody neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and myelin oligodendrocyte glycoprotein ... ...

Abstract	Background: Optic neuritis (ON) is a common feature of inflammatory demyelinating diseases (IDDs) such as multiple sclerosis (MS), aquaporin 4-antibody neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). However, the involvement of the optic chiasm (OC) in IDD has not been fully investigated. Aims: To examine OC differences in non-acute IDD patients with (ON+) and without ON (ON-) using magnetisation transfer ratio (MTR), to compare differences between MS, AQP4 + NMOSD and MOGAD and understand their associations with other neuro-ophthalmological markers. Methods: Twenty-eight relapsing-remitting multiple sclerosis (RRMS), 24 AQP4 + NMOSD, 28 MOGAD patients and 32 healthy controls (HCs) underwent clinical evaluation, MRI and optical coherence tomography (OCT) scan. Multivariable linear regression models were applied. Results: ON + IDD patients showed lower OC MTR than HCs (28.87 ± 4.58 vs 31.65 ± 4.93; Conclusion: OC microstructural damage indicates prior ON in IDD and is linked to reduced vision and thinner pRNFL.
Language	English
Publishing date	2024-04-22
Publishing country	England
Document type	Journal Article
ZDB-ID	1290669-4
ISSN	1477-0970 ; 1352-4585
ISSN (online)	1477-0970
ISSN	1352-4585
DOI	10.1177/13524585241240420
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4428: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.

Foley, Peter / Parker, Richard A / de Angelis, Floriana / Connick, Peter / Chandran, Siddharthan / Young, Carolyn / Weir, Christopher J / Chataway, Jeremy

Multiple sclerosis and related disorders

2022 Volume 63, Page(s) 103925

Abstract: Background: Evidence-based treatment of pain in people with MS presents a major unmet need.: Objective: We aimed to establish if use of Fluoxetine, Riluzole or Amiloride improved neuropathic pain outcomes in comparison to placebo, in adults with ... ...

Abstract	Background: Evidence-based treatment of pain in people with MS presents a major unmet need. Objective: We aimed to establish if use of Fluoxetine, Riluzole or Amiloride improved neuropathic pain outcomes in comparison to placebo, in adults with secondary progressive MS participating in a trial of these putative neuroprotectants. Methods: In pre-specified secondary analyses of the MS SMART phase-2b double-blind randomised controlled trial (NCT01910259), we analyzed reports of neuropathic pain, overall pain, and pain interference. Multivariate analyses included adjustment for baseline pain severity. Additionally, we explored associations of pain severity with clinical and MRI brain imaging variables. Results: 445 Participants were recruited from 13 UK neuroscience centres. We found no statistically significant benefit of active intervention on any rating of neuropathic pain, or pain overall. Compared to placebo, adjusted mean difference in pain intensity was 0.38 (positive values favouring placebo, 95%CI -0.30 to 1.07, p = 0.27) for Amiloride; 0.52 (-0.17 to 1.22, p = 0.14) for Fluoxetine; and 0.40 (-0.30 to 1.10, p = 0.26) for Riluzole. Pain severity was positively correlated with depressive symptoms (Spearman correlation 0.19, 95%CI 0.10-0.28) and fatigue (Rho 0.30, 95%CI 0.20-0.39). Conclusion: Use of Fluoxetine, Riluzole or Amiloride was not associated with improvement in neuropathic pain symptoms, in comparison to placebo.
MeSH term(s)	Adult ; Amiloride/therapeutic use ; Double-Blind Method ; Fluoxetine/therapeutic use ; Humans ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Chronic Progressive/drug therapy ; Neuralgia/drug therapy ; Neuralgia/etiology ; Riluzole/therapeutic use
Chemical Substances	Fluoxetine (01K63SUP8D) ; Amiloride (7DZO8EB0Z3) ; Riluzole (7LJ087RS6F)
Language	English
Publishing date	2022-05-28
Publishing country	Netherlands
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2645330-7
ISSN	2211-0356 ; 2211-0348
ISSN (online)	2211-0356
ISSN	2211-0348
DOI	10.1016/j.msard.2022.103925
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

De Angelis, Floriana / Plantone, Domenico / Chataway, Jeremy

CNS drugs

2018 Volume 32, Issue 6, Page(s) 499–526

Abstract: Multiple sclerosis is an immune-mediated inflammatory disease of the central nervous system characterised by demyelination, neuroaxonal loss and a heterogeneous clinical course. Multiple sclerosis presents with different phenotypes, most commonly a ... ...

Abstract	Multiple sclerosis is an immune-mediated inflammatory disease of the central nervous system characterised by demyelination, neuroaxonal loss and a heterogeneous clinical course. Multiple sclerosis presents with different phenotypes, most commonly a relapsing-remitting course and, less frequently, a progressive accumulation of disability from disease onset (primary progressive multiple sclerosis). The majority of people with relapsing-remitting multiple sclerosis, after a variable time, switch to a stage characterised by gradual neurological worsening known as secondary progressive multiple sclerosis. We have a limited understanding of the mechanisms underlying multiple sclerosis, and it is believed that multiple genetic, environmental and endogenous factors are elements driving inflammation and ultimately neurodegeneration. Axonal loss and grey matter damage have been regarded as amongst the leading causes of irreversible neurological disability in the progressive stages. There are over a dozen disease-modifying therapies currently licenced for relapsing-remitting multiple sclerosis, but none of these has provided evidence of effectiveness in secondary progressive multiple sclerosis. Recently, there has been some early modest success with siponimod in secondary progressive multiple sclerosis and ocrelizumab in primary progressive multiple sclerosis. Finding treatments to delay or prevent the courses of secondary progressive multiple sclerosis is an unmet and essential goal of the research in multiple sclerosis. In this review, we discuss new findings regarding drugs with immunomodulatory, neuroprotective or regenerative properties and possible treatment strategies for secondary progressive multiple sclerosis. We examine the field broadly to include trials where participants have progressive or relapsing phenotypes. We summarise the most relevant results from newer investigations from phase II and III randomised controlled trials over the past decade, with particular attention to the last 5 years.
MeSH term(s)	Anti-Inflammatory Agents/therapeutic use ; Humans ; Multiple Sclerosis/drug therapy ; Randomized Controlled Trials as Topic
Chemical Substances	Anti-Inflammatory Agents
Language	English
Publishing date	2018-06-30
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	1203800-3
ISSN	1179-1934 ; 1172-7047
ISSN (online)	1179-1934
ISSN	1172-7047
DOI	10.1007/s40263-018-0538-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4083: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Dimethyl fumarate may still have a role in progressive multiple sclerosis.

Plantone, Domenico / De Angelis, Floriana / Doshi, Anisha / Chataway, Jeremy

Therapeutic advances in neurological disorders

2016 Volume 9, Issue 4, Page(s) 344–345

Language	English
Publishing date	2016-04-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2442245-9
ISSN	1756-2864 ; 1756-2856
ISSN (online)	1756-2864
ISSN	1756-2856
DOI	10.1177/1756285616640396
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: New MS diagnostic criteria in practice.

De Angelis, Floriana / Brownlee, Wallace J / Chard, Declan T / Trip, S Anand

Practical neurology

2018 Volume 19, Issue 1, Page(s) 64–67

MeSH term(s)	Brain/diagnostic imaging ; History, 20th Century ; History, 21st Century ; Humans ; Magnetic Resonance Imaging/methods ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/history ; Psychiatric Status Rating Scales/history ; Spinal Cord/diagnostic imaging
Language	English
Publishing date	2018-09-22
Publishing country	England
Document type	Historical Article ; Journal Article
ZDB-ID	2170881-2
ISSN	1474-7766 ; 1474-7758
ISSN (online)	1474-7766
ISSN	1474-7758
DOI	10.1136/practneurol-2018-001945
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6001: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.

Prosperini, Luca / De Angelis, Floriana / De Angelis, Rosanna / Fanelli, Fulvia / Pozzilli, Carlo

Journal of neurology, neurosurgery, and psychiatry

2015 Volume 86, Issue 2, Page(s) 236–238

MeSH term(s)	Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Disability Evaluation ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/therapeutic use ; Magnetic Resonance Imaging ; Male ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/pathology ; Natalizumab ; Neuroimaging ; Recovery of Function/drug effects ; Recurrence ; Young Adult
Chemical Substances	Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; Natalizumab
Language	English
Publishing date	2015-02
Publishing country	England
Document type	Letter ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	3087-9
ISSN	1468-330X ; 0022-3050
ISSN (online)	1468-330X
ISSN	0022-3050
DOI	10.1136/jnnp-2014-307786
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui II Zs.93: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials.

Williams, Thomas / Alexander, Sarah / Blackstone, James / De Angelis, Floriana / John, Nevin / Doshi, Anisha / Beveridge, Judy / Braisher, Marie / Gray, Emma / Chataway, Jeremy

Trials

2022 Volume 23, Issue 1, Page(s) 644

Abstract: Background: Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the optimisation of recruitment strategies. Here we ... ...

Abstract	Background: Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the optimisation of recruitment strategies. Here we performed an observational review of our experience in recruitment for two large randomised controlled trials for people with secondary progressive multiple sclerosis. We aimed to explicitly determine those factors which can facilitate trial recruitment in progressive neurodegenerative disease. Methods: Recruitment data from the sequential MS-SMART [NCT01910259] and MS-STAT2 [NCT03387670] UK randomised controlled trials was reviewed from the largest recruiting site, University College London (UCL). The trial population was similar which allowed comparison over the two recruitment periods of 2015-2016 and 2018-2021. This included sources of referral, progress through stages of recruitment, reasons for participant ineligibility and the impact of publicity events upon recruitment. Results: In MS-SMART, 18% of patients contacted were enrolled, compared to 27% for MS-STAT2. Online registration of interest portals provided the greatest number of referrals (76% in MS-SMART, and 51% in MS-STAT2), with publicity in national media outlets producing a demonstrable increase in the number of potential participants. The introduction of an online self-screening questionnaire for MS-STAT2 resulted in 67% of potential participants (3080 of 4605) automatically determining their own ineligibility. In both studies, however, around 60% of those directly telephoned to discuss the study were not eligible, with difficulties related to travel to trial visits, or excluded medication, being the most common issues. Eighty-four percent of those deemed potentially eligible following telephone calls were enrolled in the MS-STAT2 study, compared to only 55% for MS-SMART. Conclusions: Through a detailed review of recruiting participants at the largest centre into two large randomised controlled trials with similar entry criteria, we have identified a number of approaches that may improve recruitment efficiency. We highlight here the importance of mandatory online self-screening questionnaires, a coordinated publicity campaign, and simple interventions such as eligibility checklists and appointment reminders. Recruitment approaches should be further assessed through a studies within a trial (SWAT) design. Trial registration: MS-SMART: NCT01910259 registered July 2013 and MS-STAT2: NCT03387670 registered Jan 2018.
MeSH term(s)	Humans ; London ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Chronic Progressive/diagnosis ; Multiple Sclerosis, Chronic Progressive/drug therapy ; Neurodegenerative Diseases ; Randomized Controlled Trials as Topic ; STAT2 Transcription Factor ; Telephone
Chemical Substances	STAT2 Transcription Factor ; STAT2 protein, human
Language	English
Publishing date	2022-08-09
Publishing country	England
Document type	Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-022-06588-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito